Home News Low Bleeding Profile With Asundexian Seen in Pooled Analysis back to News
minute read
Cumulative safety data from three trials testing the reversible direct factor XIa inhibitor asundexian in patients at risk for stroke or recurrent cardiovascular events suggest a better bleeding profile compared with apixaban (Eliquis; Bristol Myers Squibb) in a variety of patient types.
Topics: Press Coverage
12631 East 17th Avenue
8601
Aurora, CO 80045
303-724-1785
© 2024 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.
